Edgewood's $20M Series A; Nanoscope to pursue FDA approval for eye gene therapy later this year
2024-03-26
临床2期基因疗法
Plus, news about bluebird bio, Q32 Bio and Aquestive Therapeutics:
Edgewood Oncology’s $20M Series A:
The Brookline, MA-based biotech plans to use the money to
support
Phase 2a studies in acute myeloid leukemia and targeted breast cancer. It’s financed by Alta Partners.
— Kyle LaHucik
Nanoscope to seek FDA approval for eye gene therapy:
The Dallas-based biotech
said
its mutation-agnostic gene therapy MCO-010 passed a Phase 2b study in retinitis pigmentosa, significantly improving vision measured on an eye chart at one year at both the high and low doses compared to a sham control. It expects to submit an application for MCO-010 to the FDA in the second half of this year.
— Lei Lei Wu
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。